Identification and biological activity of the active metabolite of clopidogrel

Thrombosis and Haemostasis

Volumn 84, Issue 5, 2000, Pages 891-896

  Savi, P ^a   Pereillo, J M ^a   Uzabiaga, M F ^a   Combalbert, J ^a   Picard, C ^a   Maffrand, J P ^a   Pascal, M ^a   Herbert, J M ^a  

^a SANOFI   (France)

Author keywords

ADP; Aggregation; Clopidogrel; Metabolite; Platelets

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; CYSTEINE; DISULFIDE; DRUG METABOLITE; THIOL GROUP; TICLOPIDINE;

ANTICOAGULATION; ARTICLE; DISSOCIATION CONSTANT; DRUG BINDING SITE; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME REGULATION; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; INCUBATION TIME; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0033678468     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614133     Document Type: Article

References (26)

1. Clopidogrel, a novel antiplatelet and antithrombotic agent
2. CAPRIE Steering Committee, a randomized, blinded, trial of SR25990C versus aspirin in patients at risk of ischaemic events (CAPRIE)
3. Broad spectrum antiplatelet activity of PCR5332 and PCR4099 involves the suppression of the effects of released ADP
4. Clopidogrel hydrogenosulfate
5. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase
6. Binding of [3H]-2-methylthio ADP to rat platelets: Effect of clopidogrel and ticlopidine
7. Characterization of P2X1 purinoceptors on rat platelets: Effect of clopidogrel
8. Role of P2Y1 purinoceptor in ADP-induced platelet activation
9. The human platelet ADP receptor activates G(12) proteins
10. Evidence for the existence of two different ADP-binding sites on rat platelets
11. 32P] diphosphate to the receptor on intact human blood platelets which inhibits adenylate cyclase
12. Identification of a receptor for ADP on blood platelets by photoaffinity labelling
13. ADP receptors on platelets and ADP-selective antiaggregating agents
14. Clopidogrel: An antithrombotic drug acting on the ADP-dependent activation pathway of human platelets
15. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel
16. Structure and stereochemistry of the active metabolite of clopidogrel
17. Aggregation of blood platelets by adenosine diphosphate and its reversal
18. Methods for studying platelet shape change, aggregation, and fibrinogen binding
19. Extraction of cyclic AMP for the determination in the competitive protein binding assay
20. Influence of hepatic cytochrome P450 subfamilies induction on the microsomal hepatic metabolism and the antiaggregating activity of the thienopyridine clopidogrel (SR25990C)
21. The antiaggregating activity of clopidogrel is due to a metabolic activation by hepatic cytochrome P450-1A
22. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro
23. Non-specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro
24. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation
25. Biochemical and pharmacological properties of clopidogrel: A new ADP receptor antagonist
26. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits